Skip Ribbon Commands
Skip to main content
CIBMTR

Newsletters

Sharing knowledge. Sharing Hope.
Skip Navigation LinksHome   |   Reference Center   |   Newsletters   |   May 2014
  • Print
  • Share

May 2014 Newsletter

Volume 20, Issue 1  Table of Contents:PerspectivesGraft-vs-Host Disease Working CommitteeLymphoma Working Committee2014 BMT Tandem Meetings2013 Summary Slides Now Available on WebsiteBlood and Marrow Transplant Clinical Trials NetworkSurvey Research GroupStem Cell Therapeutic Outcomes Database2014 CIBMTR Advisory Committee MembersOur Supporters     Perspectives By Paul Martin, MD   One of my favorite calculus problems asked how to determine the steady state level of water that would accumulate in a tub at any given inflow rate if the outflow rate is proportional to pressure at the drain. I no longer know how to solve this problem, but let me explain how it relates to our work in CIBMTR. As of July 2013, the CIBMTR had 152 ongoing studies at various stages of protocol preparation, data assembly, and data analysis; 45 manuscripts in preparation after data analysis had been completed; and 28 submitted manuscripts, yielding a total of 225 active studies. At the end of this year’s BMT Tandem Meetings, the total decreased slightly to 222 active studies, indicating that the pool of active studies is currently at a steady state.  How did we accomplish this remarkable result? After all, the pool of active studies has not just one inflow and outflow, but 15 inflows and outflows, representing each of the different CIBMTR Working Committees. First, 35 studies have been published or are in press since July 2013. At the beginning of the BMT Tandem Meetings, 121 studies were under protocol preparation, data assembly, or data analysis; 50 manuscripts were in preparation; and 21 manuscripts were under review after submission, yielding a total of 192 active studies. During the meeting, 10 studies were dropped, and 40 of the 88 proposed new studies were approved. The 45% approval rate and the decision to drop 10 studies indicate that the Working Committees have taken seriously the task of identifying and giving priority to feasible studies that are likely to have the highest impact on the field. I commend the Working Committee Chairs for their leadership in conducting transparent and judicious evaluations and keeping the larger mission and goals of the CIBMTR in mind throughout the process. In addition to the 35 new publications, 50% of the active studies reached at least one milestone along the path from protocol preparation through manuscript submission during the past year, and an additional 37% have made measurable progress along the path from one milestone to the next. During the past year, 39 studies were presented at national or international meetings, and 80 have involved collaboration with external groups. During this year’s BMT Tandem Meetings, 1,529 members attended the Working Committee Meetings, an 8.7% increase from the previous year, and 38% of the attendees participated for the first time. On behalf of the Advisory Committee, I would like to congratulate the membership for these accomplishments. At the same time, we should ask, “Can we do better?”  The answer, of course, is “yes.” The lowest hanging and most valuable fruit would be to convert the 50 manuscripts in preparation and the 21 manuscripts under review into publications. We should aspire to have these 71 studies published or in press before the 2015 BMT Tandem Meetings. These studies should be replaced by inflow of new manuscripts in preparation after data analysis is completed during the current year, creating capacity to approve new studies at next year’s meeting without overflowing the tub! Return to Top     Graft-vs-Host Disease Working Committee Graft-vs-Host Disease (GVHD) is the most critical complication of allogeneic stem cell transplantation, and its occurrence prevents favorable outcomes in a large proportion of affected patients. GVHD is an entirely iatrogenic complication of allogeneic transplantation, and its prevention and treatment are of paramount importance to the transplantation community as a whole. In the last few years, increased attention has been paid to the prevention and treatment of GVHD as alternative and mismatched donors have been increasingly used in transplantation and as novel immunosuppressive agents have been developed for the treatment of the autoimmune and rheumatologic conditions. The GVHD Working Committee examines both acute and chronic GVHD outcomes across all diseases treated by allogeneic transplantation. Under the leadership of Corey Cutler, Dan Couriel, Amin Alousi, Mukta Arora, Steve Spellman, Michael Hemmer, Tao Wang, and the recent contributions of Alvaro Urbano-Ispizua, Mary Flowers, and Steve Pavletic, the GVHD Working Committee has focused on:   Novel prognostic systems and risk factors for both acute and chronic GVHD; Comparisons of GVHD incidence and outcomes of different GVHD prophylaxis regimens and stem cell sources; Overviews in the trends of GVHD as transplantation practices evolve. In recent years, the GVHD Working Committee has published seven articles (five in 2011-2013, three in 2008-2010) and presented six abstracts at the American Society of Hematology (ASH) and BMT Tandem Meetings. The committee has 11 ongoing studies with plans of completing at least 3 studies in each academic year, making it one of the most efficient and productive committees around. The GVHD Working Committee benefits from broad enrollment to the CIBMTR database. The number of allogeneic transplants from 2001-2013 total >27,000 for leukemic diseases (acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and other leukemia) and >9,000 for non-leukemia malignancies.   The GVHD Woking Committee is always seeking interesting and novel ideas for study as well as encouraging the involvement of junior investigators and those wanting to break into the field of blood and marrow transplantation and outcomes research.    Return to Top   Lymphoma Working Committee Although autologous and allogeneic hematopoietic stem cell transplantation (HCT) are key tools within the therapeutic armamentarium for patients with advanced lymphoid malignancies, growing awareness of biologic complexity coupled with an influx of new agents challenges our understanding of the optimal role and timing of HCT for lymphoma patients. Rare lymphomas, rituximab-refractory populations, demonstration of graft-versus-lymphoma effect, and the timing of autologous stem cell transplant in mantle cell and T-cell lymphomas are just some of the topics being evaluated. These concepts are exciting to explore, as reflected by an unprecedented surge in the number of submitted proposals, with 21 in 2014. Although not all proposals could be selected for discussion, the Lymphoma Working Committee was successfully able to have 12 presenters make their case to the open group, with vigorous debate and discussion on nearly all topics at the BMT Tandem Meetings in Grapevine, Texas, this past February. The Lymphoma Working Committee, one of the first established within the CIBMTR, focuses on cellular therapy for these diseases and has conducted numerous studies addressing a wide range of issues in the field of HCT for patients with Hodgkin and non-Hodgkin lymphoma. Several treatment paradigms widely practiced in the field of HCT in the modern era are largely or solely based on data generated by the Lymphoma Working Committee, including autologous HCT for primary refractory Hodgkin lymphoma, high-dose therapy for lymphoid malignancy cases with a history of central nervous system involvement, and salvage autologous HCT in relapsed mantle cell lymphoma, to name a few.   The Lymphoma Working Committee is led by 3 co-chairs: David Maloney, MD (University of Washington); Sonali Smith, MD (University of Chicago); and Anna Sureda, MD (Institut Català d'Oncologia). The committee's Scientific Director is Mehdi Hamadani, MD, and the statisticians are Rodney Sparapani, PhD, and Jeanette Carreras, MPH. The Lymphoma Working Committee has identified the following as its research foci and priorities:   Role and timing of HCT in the era of novel targeted therapies; Alternative donor transplantation in lymphoid malignancies; Role of functional imaging in predicting outcomes of allogeneic HCT in lymphoid malignancies; Promoting and encouraging participation of Hematology and Oncology fellows and junior faculty in the scientific endeavors of the committee. 2013 was a great year for the Lymphoma Working Committee, with six published manuscripts (including one in British Journal of Haematology, two in Journal of Clinical Oncology, and three in Biology of Blood and Marrow Transplantation) and three abstract presentations at ASH and the BMT Tandem Meetings. Reflecting the group’s goal of distributing projects, these six publications included five different first authors. The committee has seven ongoing studies with ambitious plans of completing at least six studies by July 2015. The enrollment to the CIBMTR database for histologies relevant to the committee has remained robust. From 2001-2013, the number of allogeneic transplants total >10,600 and autologous transplants >18,800. These numbers strongly support the ongoing need to fully understand the role and timing of HCT in mature lymphoid malignancies. The Lymphoma Working Committee is interested in studies designed to answer questions that are highly relevant for advancing patient care, particularly in areas in which data from prospective trials are not available, and for providing hypothesis-generating data that inform future prospective HCT trials.   Return to Top 2014 BMT Tandem Meetings By D’Etta Waldoch, CMP    The 2014 BMT Tandem Meetings, held in Grapevine, Texas, are thrilled to report another record-breaking registration of 2,950! The 2014 BMT Tandem Meetings, held February 26 – March 2 at the Gaylord Texan Hotel and Convention Center in Grapevine, Texas, provided an outstanding scientific program and peripheral sessions for BMT pharmacists, center administrators, coordinators, investigators, medical directors, clinical research professionals / data managers, transplant nurses, and advanced practitioners. The CIBMTR is proud to announce that the 2014 ASBMT Lifetime Achievement Award was presented to Chief Scientific Director, Mary M. Horowitz, MD, MS. Dr. Horowitz received a standing ovation for her acceptance presentation, which provided an overview of CIBMTR’s roots and early years up to the present. The 2014 Mortimer M. Bortin Lecture, entitled “A View from the Antipodes: Registries, Transplants and Beyond,” was presented by Jeffrey Szer, MBBS, Royal Melbourne Hospital, Parkville, Australia. Lecturers are chosen on the basis of their contributions to our understanding of graft-versus-tumor effects and / or the advancement of clinical HCT research. Mammen Chandy, MD, Tata Medical Center, Kolkata, India, was presented the CIBMTR’s Distinguished Service Award for 2014. Dr. Chandy received the award for his service and commitment to CIBMTR, dedication to advancing the field of HCT research, and leadership in promoting stem cell transplantation throughout India.   The 2014 Meetings appreciated the second highest number of abstract submissions – 528 from 30 countries. Recipients of the CIBMTR Best Abstract Awards for Clinical Research, supported by a grant from WellPoint, Inc. were:  Sung-Yun Pai, MD – “Retrospective Study of 240 Patients with Severe Combined Immunodeficiency Transplanted from 2000-2009: A Report from the Primary Immune Deficiency Treatment Consortium of North America.” Joseph Pidala, MD, MS – “HLA-Mismatch is Associated with Worse Outcomes after Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis.” Carlos Ramos, MD – “Clinical Responses in Patients Infused with T Lymphocytes Redirected to Target Kappa-Light Immunoglobulin Chain.” Attendance at concurrent CIBMTR Working Committee Meetings reached new heights, as the Working Committees consolidated from 19 to 15. All registered attendees with an interest are welcome to join the Working Committee Meetings.   Clinical Research Professionals and Data Managers were treated to Texan-style line dancing during the Mentor’s Reception on Tuesday evening, led by long-time CIBMTR supporter, Andrew Koser. Our own Tom Moerke (Milwaukee Campus) and Tony Wirth (Minneapolis Campus) formed the new duo of The Brat Boys, as they sang hematopoietically-correct lyrics to country song, The Shake.  (Email D’Etta if you’d like a copy of the lyrics.)   The new Information Technology Forum, chaired by Colleen O’Neill and Erik Bergman, was held on Wednesday, February 26. Plans for the 2015 IT Forum are well underway.   This year in addition to the printed program guide, attendees were able to download the Annual Meeting App, BMTTANDEM, on the Apple App Store or Google Play Store. The App allowed registered attendees access to the meeting program schedule and general information, session evaluations, speaker information, exhibit booth locations mapped out on the exhibit hall floor plan, messaging to other attendees, and the ability to create a personal schedule.   Keep an eye on www.cibmtr.org or www.asbmt.org as the 2015 program firms up over the upcoming months. Register and make housing reservations before the increased rates take effect on October 9th. Don’t forget to reserve your ticket to the Saturday evening Tandem Reception aboard the USS Midway aircraft carrier – it’s sure to be a memorable venue!   We look forward to seeing you at the Manchester Grand Hyatt in San Diego next February 11-15!    ​Mary M. Horowitz, MD, MS, CIBMTR Chief Scientific Director, (left) received the 2014 ASBMT Lifetime Achievement Award from Fred LeMaistre, MD, ASBMT President ​ Jeffrey Szer, MBBS, Royal Melbourne Hospital, Parkville, Australia, presented the 2014 Mortimer M. Bortin Lecture, entitled "A View from the Antipodes: Registries, Transplants and Beyond" ​ Mammen Chandy, MD, Tata Medical Center, Kolkata, India, (center) received the 2014 CIBMTR Distinguished Service Award from Mary Horowitz, MD, MS, CIBMTR Chief Scientific Director, and Thomas Shea, MD, CIBMTR Chair ​ Tom Moeke, CIBMTR Milwaukee, and Tony Worth, CIBMTR Minneapolis, formed The Brat Boys and sang hemtopoietically-correct lyrics to The Shake at the Mentor's Reception   Line Dancing at the Mentor's Reception for Clinical Research Professionals and Data Managers     Return to Top     2013 Summary Slides Now Available on Website   We are pleased to announce that the 2013 Summary Slides are now available on the CIBMTR website. The Summary Slides are an annual report on data submitted to the CIBMTR by centers worldwide, and they describe information related to practices and general survival outcomes after HCT. The current edition includes transplants performed prior to 2013. Slides 3 to 23 exhibit data on the frequency of transplants according to age, donor and transplant type, graft source and disease, and early outcomes, such as 100-day mortality by disease and transplant type. All frequencies represent first transplants registered with the CIBMTR during the period, except when stating frequencies in the US. Slides 3, 8, and 9 represent estimated frequencies of total number of transplants expected in the US. Slides 24 to 40 include overall survival outcomes according to disease, disease status, donor type, year of transplant, and conditioning regimen intensity. Comparisons across survival curves are univariate and do not adjust for all potentially important factors; consequently, results should be interpreted cautiously. Additional information on the Summary Slides, including how to properly cite them, is provided on the CIBMTR website.    Return to top    Blood and Marrow Transplant Clinical Trials NetworkBy Amy Foley The Blood and Marrow Transplant Clinical Trials Network (BMT CTN), with its 20 core and approximately 100 affiliate centers, has enrolled over 6,000 patients since 2003. The CIBMTR shares administration of the BMT CTN Data and Coordinating Center with NMDP and The EMMES Corporation. These three organizations together support all BMT CTN activities.   The BMT CTN Steering Committee is currently under the leadership of Chair Fred Appelbaum (Fred Hutchinson Cancer Research Center) who just started his two year term. Steve Devine (Ohio State University Medical University) will continue to serve as Vice Chair, and Ginna Laport (Stanford University) is serving as Immediate Past Chair.   2014 State of the Science SymposiumThe BMT CTN hosted a two day State of the Science Symposium (SOSS) during the BMT Tandem Meetings. The Symposium had two purposes: 1) review recent scientific advances in the field of stem cell transplantation and 2) identify the most compelling opportunities for clinical research appropriate for the BMT CTN in the next several years. Fred Appelbaum served as the SOSS Chair, and there were over 300 attendees. Thirteen committees were convened to review the landscape and present study proposals:  Clinical Trial Design Comorbidity and Regimen Related Toxicity Gene and Cell Therapy GVHD Infection / Immune Reconstitution Late Effects / Quality of Life / Economics Leukemia Lymphoma Multiple Myeloma Non-Malignant Diseases Optimal Donor and Graft Source Pediatric Transplant – Indications / Approaches Pediatric Transplant – Outcomes / Late Effects Twelve of the committees submitted 1-3 clinical trial proposals for review at the Symposium. The thirteenth committee, Clinical Trial Design, served as an advisory group to the other committees. Prior to the Symposium, 20 external reviewers were invited to participate and review concepts in the areas of their expertise. These reviewers, none of whom are involved directly with the BMT CTN (and the majority of whom are from outside the US), reviewed the concepts prior to the Symposium and provided feedback to the Committee Chairs. At the Symposium, each Committee Chair presented a summary of their concepts; the reviewers presented their feedback, and then the conversation was opened to the audience for their input. Each concept was scored during the Symposium by Committee Chairs, external reviewers, and NIH Project Officers. Immediately following the Symposium, this group met to review the scores and prioritize the top studies. The prioritized concepts were subsequently reviewed and agreed upon by the BMT CTN Executive and Steering Committees.   A manuscript describing the Symposium process and details of the prioritized concepts is drafted and will be submitted for publication soon. These 2014 priority concepts will serve as a road map for future studies recommended for implementation by the US transplant community using the resources of the BMT CTN, National Cancer Institute Cooperative Groups, and other programs. Dr. Appelbaum thanks all the participants for making the SOSS a success, “The State of the Science Symposium was a true collaborative effort of US investigators within and outside the Network, international colleagues, and NIH sponsors. We’re excited about the robust portfolio of prioritized concepts that resulted from this undertaking.”   Clinical Trials: Open Enrollment The BMT CTN encourages widespread transplant community participation in clinical trials. If your center is interested in participating, please visit the BMT CTN website. There are eight trials open, one released to sites, and six in development. The following BMT CTN trials are open or will soon be opened for enrollment:  BMT CTN 0601 - Phase II unrelated donor HCT for patients with sickle cell using reduced-intensity conditioning BMT CTN 0903 – Phase II study for allogeneic transplantation for hematologic malignancy in HIV+ patients BMT CTN 1101 - Phase III study comparing HLA-haploidentical related donor bone marrow vs. double umbilical cord blood (haplo vs. double cord) with RIC for patients with hematologic malignancy BMT CTN 1102 - Biologic assignment trial comparing RIC HCT to hypomethylating therapy or best supportive care in patients aged 50-75 with intermediate-2 and high risk myelodysplastic syndrome BMT CTN 1202 - Prospective cohort of biologic samples for the evaluation of biomarkers predicting risk of complications and mortality following allogeneic HCT BMT CTN 1203 - Randomized Phase II study of novel approaches for GVHD prophylaxis compared to CIBMTR controls BMT CTN 1204 - Reduced-intensity conditioning for children and adults with hemophagocytic syndromes or selected primary immune deficiencies  BMT CTN 1205 - Easy-to-read informed consent for HCT clinical trials BMT CTN 1304 / DFCI 10-106 - Phase III study comparing conventional dose treatment using a combination of lenalidomide, bortezomib, and dexamethasone (RVD) to high-dose treatment with peripheral stem cell transplant in the initial management of myeloma in patients up to 65 years [Note: this study is managed by Dana Farber Cancer Institute, but BMT CTN has endorsed the study and is providing accrual credit to BMT CTN centers] Recent Presentation EBMT Annual Meeting, March 2014 BMT CTN 0302 and 0802: John Levine  A New Ann Arbor Grading System Uses Biomarkers to Risk Stratify Patients for Non Relapse Mortality at the Onset of Acute Graft Versus Host Disease  Publications There are 38 BMT CTN published articles, including 10 primary analyses. The following manuscripts were accepted / published since the last CIBMTR newsletter:   Mauskopf, J, Chirila C, Graham J, Gersten ID, Leather H, Maziarz RT, Baden LR, Bolaños-Meade J, Brown JMY, Walsh TJ, Horowitz MM, Kurtzberg J, Marr KA, Wingard JR. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. American Journal of Health-System Pharmacy. 2013 Sep 1; 70(17):1518-1527. Ferrara J. Blood and Marrow Transplant Clinical Trials Network: Progress since the State of the Science Symposium 2007. Biology of Blood and Marrow Transplantation. 2014 Feb; 20(2):149-153. Epub 2013 Nov 12.  Yanik GA, Horowitz MM, Weisdorf DJ, Logan BR, Ho VT, Soiffer RJ, Carter SL, Wu J, Wingard JR, DiFronzo NL, Ferrara JL, Giralt S, Madtes DK, Drexler R, White ES, Cooke KR. A randomized double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: Enbrel (Etanercept) for the treatment of idiopathic pneumonia syndrome following allogeneic stem cell transplantation. A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol. Biology of Blood and Marrow Transplantation. Epub 2014 Mar 11. Roth JA, Bensink ME, O’Donnell PV, Brunstein CG, Fuchs EJ, Eapen M, Ramsey SD. Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. Journal of Comparative Effectiveness Research. 2014 Mar 1; 3(2):135-144.  Waller EK, Logan BR, Harris WA, Devine SM, Porter DL, Mineishi M, McCarty JM, Gonzalez CE, Spitzer TR, Krijanovski OI, Linenberger ML, Woolfrey A, Howard A, Wu J, Confer DL, Anasetti A. Transplanting more donor pDC or naïve T-cells in unrelated-donor marrow but not G-CSF-mobilized bloodgrafts is associated with better survival. Journal of Clinical Oncology. [In press].    Return to Top    Survey Research GroupBy Becky Drexler and Deborah Mattila   The Survey Research Group (SRG), a team within the Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI BMT), is responsible for collecting high quality, scientifically valid data from registry members and donors as well as patients and their families. The SRG utilizes standardized and semi-structured telephone interviews as well as self-administered questionnaires, and they collect research samples, such as buccal swabs and study lab kits. While many of their research studies are part of the RCI BMT portfolio, the SRG has also partnered with the BMT CTN, NMDP Bioinformatics Research, and Health Services Research.   The SRG consists of a supervisor, research assistant, and five research interviewers. This team conducts surveys regarding medical health, quality of life, and healthcare utilization, and it supports the collection of study materials, such as consent forms and buccal swab kits. The SRG conducts assessments by phone and paper and is currently exploring solutions to conduct online assessments that provide robust and flexible administration, integration with existing technologies, and data security.   The SRG is currently working on nine research studies. By far the largest is the Long-Term Donor Follow Up (LTDFU) study. For this study, research interviewers contact enrolled, unrelated bone marrow and peripheral blood stem cell donors every two years to conduct a short medical questionnaire, and the interviewers follow up to verify diagnoses of malignancy, autoimmune, or thrombotic events. The LTDFU study currently has more than 17,000 enrolled subjects, with SRG following up on more than 10,000 of them. Follow-up assessments are scheduled to continue through October 2020. The SRG is particularly proud of its role in completing retrospective enrollment for this study, contacting and gathering consent forms for over 9,500 individuals who donated prior to October 2010 when the LTDFU study started.   The SRG’s newest project is performing the quality of life study within the BMT CTN 1102 clinical trial. For this study, the SRG contacts patients at 6 time points between baseline and 36 months post-enrollment to conduct a 20 minute quality of life interview. Enrollment for this study began in March 2014 and will accrue 450 subjects.   The SRG plays a key role in the overall success and productivity of the RCI BMT team by providing a unique resource, which investigators should consider utilizing when developing studies.      Return to Top     Stem Cell Therapeutic Outcomes Database By J Douglas Rizzo, MD, MS, and Carol Doleysh, BS, CPA The SCTOD is part of the US Health Resources and Services Administration-funded CW Bill Young Cell Transplantation Program that collects data on all allogeneic hematopoietic cell transplants performed in the US and on transplants done elsewhere using cellular products that originated in the US. Several activities of the SCTOD, including center outcomes, registry models, and Office of Management and Budget re-approval of SCTOD forms, are highlighted below.   Center Outcomes Outcomes reporting in allogeneic HCT is necessary to provide information requested by patients, insurers, and government agencies and to comply with current laws. The SCTOD contract requires the CIBMTR to conduct an analysis of one-year survival rates at each transplant center in the US annually. The report generated by the CIBMTR is meant to be useful as a quality improvement tool for transplant centers. The data are also made available to the public at http://bethematch.org/access. An un-blinded version of the 2013 Center-Specific Outcomes Report, which includes first allogeneic HCT performed between 2009 and 2011, was recently distributed to Center Directors and US Payors. This is consistent with the goal of the CIBMTR to increase transparency of the Center Outcomes Report. We anticipate this will reduce requests from payors directly to transplant center staff to provide data about their center-specific survival report and reduce potential transcription errors using data taken from the current website. In order to be included in the analysis, transplant centers were required to have at least one year of follow-up on more than 90% of related and unrelated HCT recipients. A description of the methodology used in generating this report can be found on the CIBMTR website.   Registry Models A manuscript presenting the likelihood of finding a donor-recipient HLA-match for unrelated adult donor or cord blood HCT has been accepted for publication in the New England Journal of Medicine. This manuscript is built upon a report of the US Adult Donor Registry and Cord Blood Inventory that was generated for the CW Bill Young Cell Transplantation Program. This accomplishment highlights the value of the Program to the medical community.  The next iteration of this report, which will analyze the size, composition, and growth rate of the National Cord Blood Inventory and Adult Donor Registry, is underway. Among the goals of the report are to provide specific recommendations for recruitment activity and to determine the probability that patients of specific racial/ethnic groups will find suitably HLA-matched stem cell products.   OMB Approval Re-approval for CIBMTR data collection forms used to support the objectives of the SCTOD was received from the Office of Management and Budget on January 28, 2014.  The new expiration date is January 31, 2017.   Return to Top  2014 CIBMTR Advisory Committee MembersThe Advisory Committee, made up of members from across the globe, maintains careful oversight of the CIBMTR research agenda. The 2014 committee members are listed on the CIBMTR website, and we sincerely thank all of our committee members for their time and efforts, particularly the following individuals who completed their service in February.  Thomas Shea, MD - Chair Barry Schatz - Patient / Family Representative Alan Leahigh - Business Representative    Return to Top    Our Supporters The CIBMTR is supported by Public Health Service Grant / Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant / Cooperative Agreement 5U10HL069294 from NHLBI and NCI;  a contract HHSH250201200016C with Health Resources and Services Administration (HRSA / DHHS); two Grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research; and grants from our corporate and private contributors, which are listed on the CIBMTR website.     Return to Top    ​​​​​​​​​​

Last Updated: 12/22/2014 4:06 PM
CIBMTR